Director, Feldman, WWJ discussed on Newsradio 950 WWJ 24 Hour News

Automatic TRANSCRIPT

Feldman report on WWJ newsradio nine fifty we've talked about soft skills before able to communicate solve problems change direction with these when needed at Bosch USA Kavita pad kee director of learning and development says they've added another soft skill leadership just in the last two years we've started really focusing on this concept of leading where you are and that really means that you don't have to have a certain title or be at a certain level within the organization in order to lead and we really want to promote this concept across different departments and different groups during a panel discussion at the university of Michigan Dearborn college of business Kabita Paki said workers need to be comfortable being uncomfortable you may not know everything about the situation that you're going into but to be able to be adaptable in your mindset and thinking and just be comfortable knowing that you may not know everything and that's okay they'll figure it out with the Feldman report I'm Marie Feldman WWJ newsradio nine fifty Dr Tony Fauci director of the National Institute of allergy and he's speaking right now part of the Cova de nineteen task force that's happening in Washington we take you to the nation's capital get a get a rebound or it might cycle into the next season so what are we going to do to prepare ourselves for that one of the most important things is one that I mentioned several times from this podium and that is to clarify a bit about the timeline for vaccines and would that have any real impact on what we would call the rebounds what we call a cycling in the season certainly for sure a vaccine is not gonna help us now next month the month after but as I mentioned to you we went into a phase one trial and I I keep referring to one vaccine there's more than one there's a couple of handfuls of vaccines at different stages of development but they're all following the same course in the course is your first go in to a phase one trial to see if it's safe you have very few people forty five people within a certain age group all healthy none at really any great risk of getting infected the reason you do that because you want to make sure that it's safe then the next thing you do in that takes about three months easily maybe more so that's going to bring us into the beginning or middle of the summer then you go to a phase two trial or what we say to three which means we'll put a lot of people in there now we hope that there aren't a lot of people getting infected but it is likely there will be somewhere in the world with that's going on so it's likely that we will get what's called an efficacy signal and we will know whether or not it actually works if in fact it does we hope to Russia to be able to have some impact on recycling in the next season and like I said that could be a year to a year and a half I'm not changing any of the dates that I mention but one of the things that we are going to do that you need to understand that has been a stumbling block for previous development of vaccines and that is even before you know something works at risk you have to start producing it because once you know it works you can't say great it works now give me another six months to produce it so we're working with a variety of companies to take that risk we didn't take it with Zeke and that's why you know we have a nice ego vaccine but we don't have enough to do it because there's no Zeke around same with sars so that's one of the things were really going to push on is to be able to have it ready if in fact it works now the issue of safety something that I want to make sure the American public understands it's not only safety when you inject somebody and they get maybe an idiosyncratic reaction they get a little allergic reaction they get pain this safety associated does the vaccine make you worse in there are diseases in which you vaccinate someone they get infected with what you're trying to protect them with and you actually enhance the infection you can get a good feel for that in animal models so that's going to be indisposed at the same time that we're testing we're gonna try and make sure we don't have enhancement the worst possible thing you could do is vaccinate somebody to prevent infection and actually make them worse next and finally with regard I'll go get you your question finally with regard to therapies I mean we keep getting asked about therapies is a whole menu of therapies that are going to clinical trials as I've told you all that R. repeated again the best way to get the best drug as quickly as possible is to do a randomized control trial so that you know is it safe and it's effective if it's not effective get it off the board and go to the next thing if it is effective get it out to the people that need it so you're gonna be hearing over the next month or more about different drugs they're going to go into these randomized controlled trials and I feel confident knowing about what this virus is and what we can do with it that we will have some sort of therapy that give at least a partial if not a very good protection in in preventing progression of disease and we'll be back here talking about that a lot I'm sure thank you so much don't you tackle some **** just depends what you're saying about this idea of race drug manufacturer using them at some point.

Coming up next